Analytical Data
-
Gene name
KAZALD1
- Application
-
Alternative Names
BONO1; FKSG28; FKSG40
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q96I82
-
Expression Region
Arg31~Tyr304
-
Molecular Weight
37kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
KAZALD1, a gene that encodes a Kazal-type serine protease inhibitor, has gained attention in recent years due to its potential roles in various physiological and pathological processes. This protein is primarily expressed in epithelial tissues, where it is believed to play a crucial role in modulating protease activity, thereby influencing inflammatory responses, tissue remodeling, and cancer progression. Research has indicated that KAZALD1 may contribute to the regulation of immune responses, as it can inhibit serine proteases involved in the activation of inflammation and immune signaling pathways. Moreover, aberrant expression of KAZALD1 has been associated with several cancers, suggesting its potential as a biomarker for tumorigenesis and a target for therapeutic intervention. The recombinant expression of KAZALD1 protein has become a focal point for elucidating its structure-function relationship and understanding its interactions with proteases. By producing this protein in a laboratory setting, researchers can investigate its inhibitory mechanisms, binding affinities, and biological roles in greater detail. Such studies could unveil new insights into the dual roles of KAZALD1 in both normal physiological processes and disease states, paving the way for novel therapeutic strategies that harness its inhibitory properties. The ongoing investigations into the characteristics and implications of KAZALD1 are thus pivotal for advancing the understanding of its biological significance and exploring its potential applications in medical science.
